<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Santhera Pharmaceuticals Holding Ag — News on 6ix</title>
    <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag</link>
    <description>Latest news and press releases for Santhera Pharmaceuticals Holding Ag on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 05:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/santhera-pharmaceuticals-holding-ag" rel="self" type="application/rss+xml" />
    <item>
      <title>Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-positive-aifa-board-decision-on-reimbursement-of-agamreer-vamorolone-in-italy</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-positive-aifa-board-decision-on-reimbursement-of-agamreer-vamorolone-in-italy</guid>
      <pubDate>Tue, 28 Apr 2026 05:01:00 GMT</pubDate>
      <description>Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the treatment of patients with Duchenne muscular dystrophy (DMD) aged 4 years and older in Italy. AGAMREE is a novel molecule designed to deliver the anti-inflammatory benefits typically associated with glucocorticoids while potentially reducing the risk of adverse effects linked to th</description>
    </item>
    <item>
      <title>Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025</guid>
      <pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global expansion accelerates Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Dario Eklund, CEO of Santhera, said: “Our strong performance in 2025 reflects the continued momentum of AGAM</description>
    </item>
    <item>
      <title>Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-marc-clausse-as-chief-commercial-officer-to-lead-next-phase-of-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-marc-clausse-as-chief-commercial-officer-to-lead-next-phase-of-growth</guid>
      <pubDate>Tue, 10 Mar 2026 06:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years with Santhera and will remain available to support an orderly transition over the coming months. Proven commercial leadership to drive Santhera’s next phase of growth Marc Clausse brings over 25 years of international experience in the life sciences industry,</description>
    </item>
    <item>
      <title>AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/agamreer-vamorolone-data-presented-at-mda-2026-confirm-comparable-long-term-effectiveness-for-up-to-8-years-of-treatment-with-clinically-meaningful-safety-advantages-in-duchenne-muscular-dystrophy</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/agamreer-vamorolone-data-presented-at-mda-2026-confirm-comparable-long-term-effectiveness-for-up-to-8-years-of-treatment-with-clinically-meaningful-safety-advantages-in-duchenne-muscular-dystrophy</guid>
      <pubDate>Mon, 09 Mar 2026 06:00:00 GMT</pubDate>
      <description>Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation80% fewer patients with vertebral fractures (8.1% vs 41.9% on deflazacort, p=0.0082)Maintenance of normal height with 12.17 cm mean height advantage vs classic corticosteroids where significant stunting was observed (p&lt;0.0001) Cataracts in 5.3% vs 37.8% patients, significantly lower than deflazacort (p=0.015); no glaucoma observed Pratteln, Swit</description>
    </item>
    <item>
      <title>Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-proposed-inclusion-and-reimbursement-of-agamreer-vamorolone-within-spains-national-health-system-for-the-treatment-of-duchenne-muscular-dystrophy</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-proposed-inclusion-and-reimbursement-of-agamreer-vamorolone-within-spains-national-health-system-for-the-treatment-of-duchenne-muscular-dystrophy</guid>
      <pubDate>Fri, 27 Feb 2026 06:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® (vamorolone), in the pharmaceutical coverage of the Spanish National Health System, making it eligible for reimbursement. The conditions for such inclusion will be determined in a resolution by the Directorate-General of Pharmacy at the Spanish Ministry of Health. The company expects to receive the dr</description>
    </item>
    <item>
      <title>Santhera Appoints Stifel as Corporate Finance Advisor</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-stifel-corporate-finance-060000646</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-stifel-corporate-finance-060000646</guid>
      <pubDate>Tue, 10 Feb 2026 06:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, February 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced the appointment of Stifel Nicolaus Europe Limited (“Stifel”) as corporate finance advisor with a focus on capital markets and international institutional investors. Swiss based Octavian AG (“Octavian”) will continue to act as corporate finance advisor to the Company, working alongside Stifel to help broaden investor reach. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmac</description>
    </item>
    <item>
      <title>Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-receives-swissmedic-approval-agamree-060000869</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-receives-swissmedic-approval-agamree-060000869</guid>
      <pubDate>Thu, 15 Jan 2026 06:00:00 GMT</pubDate>
      <description>Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Dario Eklund, Chief Executive Officer of Santhera, commented: “As a proudly Switzerland-based business, securing Swissmedic approval represents an important achiev</description>
    </item>
    <item>
      <title>Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-licenses-agamree-vamorolone-nxera-071600489</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-licenses-agamree-vamorolone-nxera-071600489</guid>
      <pubDate>Thu, 08 Jan 2026 07:16:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, Switzerland, January 8, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces it has signed an exclusive licensing agreement with Nxera Pharma UK Ltd. (“Nxera”) for the development, manufacturing and commercialization of AGAMREE® (vamorolone) for the treat</description>
    </item>
    <item>
      <title>Santhera Closes USD 13 Million Royalty Monetization Agreement</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-closes-usd-13-million-060000644</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-closes-usd-13-million-060000644</guid>
      <pubDate>Wed, 05 Nov 2025 06:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® (vamorolone). The agreement was initially secured in September 2025 with R-Bridge, an affiliate of CBC Group, covering 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals, Inc. in North America and Sperogenix Therapeutics Ltd in China. Since initially securin</description>
    </item>
    <item>
      <title>Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/five-data-agamree-vamorolone-patients-063100095</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/five-data-agamree-vamorolone-patients-063100095</guid>
      <pubDate>Tue, 04 Nov 2025 06:31:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroids Pratteln, Switzerland, November 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today reported positive topl</description>
    </item>
    <item>
      <title>Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-biomedica-distribution-050000575</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-biomedica-distribution-050000575</guid>
      <pubDate>Thu, 09 Oct 2025 05:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable acce</description>
    </item>
    <item>
      <title>Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-approval-canada-agamree-050000174</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-approval-canada-agamree-050000174</guid>
      <pubDate>Fri, 03 Oct 2025 05:00:00 GMT</pubDate>
      <description>Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for th</description>
    </item>
    <item>
      <title>Santhera Provides Update on Convertible Bond Issued on 23 September 2025</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-provides-convertible-bond-issued-050000773</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-provides-convertible-bond-issued-050000773</guid>
      <pubDate>Thu, 25 Sep 2025 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced on 23 September 2025: Details: The conversion price has been set at CHF 13.5446, representing a 10% premium to the volume-weighted average price (VWAP) of Santhera’s shares on 23 September 2025. The coupon is 7%, reflecting a reduction compared with the previous bond.The aggregate principal amount</description>
    </item>
    <item>
      <title>Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-half-2025-financial-062900405</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-half-2025-financial-062900405</guid>
      <pubDate>Tue, 23 Sep 2025 06:29:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2025, reports on progress with AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) and provides updates on its corporate and financing ini</description>
    </item>
    <item>
      <title>Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-chf-20-million-050000432</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-chf-20-million-050000432</guid>
      <pubDate>Tue, 23 Sep 2025 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LR Highlights: Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rolloutDemand for AGAMREE® (vamorolone) in US/China ahead of plan; increased inventory needs and launch timing shifts drive need for incremental growth capital Pratteln, Switzerland, September 23, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces new financing agreements with R-Bridge, an affiliat</description>
    </item>
    <item>
      <title>Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-enters-agreement-ikris-pharma-050000321</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-enters-agreement-ikris-pharma-050000321</guid>
      <pubDate>Fri, 29 Aug 2025 05:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The agreement between Santhera and Ikris has a 5-year term and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to b</description>
    </item>
    <item>
      <title>Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-uniphar-distribution-050000630</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-uniphar-distribution-050000630</guid>
      <pubDate>Tue, 19 Aug 2025 05:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, 19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following</description>
    </item>
    <item>
      <title>Santhera extends Highbridge convertible bond to 30th September 2025</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-extends-highbridge-convertible-bond-050000262</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-extends-highbridge-convertible-bond-050000262</guid>
      <pubDate>Fri, 15 Aug 2025 05:00:00 GMT</pubDate>
      <description>Ad hoc announcement pursuant to Art. 53 LRA Pratteln, Switzerland, 15 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that by mutual agreement the Company and Highbridge Capital Management, LLC (Highbridge) have decided to extend the maturity date of the existing CHF 7 million private convertible bond, that has a strike price of CHF 10.00, to 30th September 2025. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the developmen</description>
    </item>
    <item>
      <title>Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-gen-distribution-050000187</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-secures-agreement-gen-distribution-050000187</guid>
      <pubDate>Wed, 13 Aug 2025 05:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Supply and sales by GEN are expected to start in the first half of 2026, initially on a named patient basis, followed by commercial sales. Santhera ha</description>
    </item>
    <item>
      <title>Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting</title>
      <link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-shareholders-approve-board-proposals-160000478</link>
      <guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-shareholders-approve-board-proposals-160000478</guid>
      <pubDate>Tue, 20 May 2025 16:00:00 GMT</pubDate>
      <description>Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company’s share capital. Approval of the 2024 Annual Report and discharge of corporate bodies The shareholders approved the Annual Report, the annual financial s</description>
    </item>
  </channel>
</rss>